Registry for drug response profiling in pediatric blood cancers
Drug Response Profiling (DRP) Registry Zurich for Hematological Malignancies
This study is testing how well different cancer drugs work on blood cancer cells from kids to help find the best treatment for those who haven't responded to other therapies.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | N/A to 40 Years |
| Sex | All |
| Sponsor | University Children's Hospital, Zurich Academic / other |
| Locations | 1 site (Zurich, Canton of Zurich) |
| Trial ID | NCT06550102 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on drug response profiling (DRP) for pediatric patients with hematological malignancies. It involves isolating primary cancer cells from patients and screening them ex vivo using automated fluorescence microscopy to assess drug sensitivity. The study aims to integrate drug sensitivity data with genetic information to provide personalized treatment options for patients with refractory disease. By evaluating the effectiveness of various chemotherapeutic agents, the study seeks to determine the feasibility of real-time drug response profiling in clinical settings.
Who should consider this trial
Good fit: Ideal candidates include pediatric and adult patients under 40 years old diagnosed with hematological malignancies such as leukemia, myeloma, or lymphoma.
Not a fit: Patients who do not have informed consent for participation or those with hematological malignancies outside the specified age range may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective treatment options for patients with blood cancers.
How similar studies have performed: Other studies utilizing drug response profiling in hematological malignancies have shown promising results, indicating potential for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pediatric and adult patients below the age of 40 years * Diagnosis of hematological malignancy (primary, relapsed or refractory) including leukemia, myeloma or lymphoma * Tumor material collected as part of routine diagnostics and willingness to donate tumor material for translational research * Patient and/or guardian has signed the informed consent of the DRP registry or of a clinical trial which includes DRP as add-on research. Exclusion Criteria: * Missing informed consent for the registry or of a clinical trial which includes DRP as add-on research
Where this trial is running
Zurich, Canton of Zurich
- University Children's Hospital Zurich — Zurich, Canton of Zurich, Switzerland (Recruiting)
Study contacts
- Study coordinator: Jean-Pierre Bourquin, MD, PhD
- Email: Jean-Pierre.Bourquin@kispi.uzh.ch
- Phone: 0041 44 2667304
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.